Why the study?
Does slow intravenous infusion of epirubicin reduce acute toxicity compared to bolus injection in patients with advanced breast cancer?
Does slow intravenous infusion of epirubicin reduce acute toxicity compared to bolus injection in patients with advanced breast cancer?
Slow intravenous infusion of epirubicin reduces acute toxicity compared to bolus injection in advanced breast cancer patients.
Favors slow epirubicin infusion over bolus to cut acute toxicity; confirms benefit and supports practice change in advanced breast cancer.
A low-intervention policy for Hickman catheter maintenance has been evaluated and found to be safe and cost effective. A simple, lightweight, disposable device has been used for 24–hour ambulatory home infusion. Implementation of this policy as part of a prospective randomized trial of single-agent chemotherapy in advanced breast cancer has demonstrated that slow intravenous infusion reduces the acute toxicity of epirubicin when compared with bolus injection.
No takes yet. Share an insight, caveat, or question.
Ebbs et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: